"New Test Developed at Dana-Farber/Brigham and Women's Cancer Center Speeds Treatment Decisions for Blood Cancer Patients," Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center

In a major advance in the care of these patients, physicians at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) have begun using Rapid Heme Panel, a high-tech genetic test that provides, within a matter of days, an unprecedented amount of critical information to aid the choice of treatment. Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center is one of the 25 NCCN Member Institutions. ...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news